Heron Therapeutics, Inc. HRTX today announced that data from
Heron's recently completed MAGIC Study of SUSTOL®
(granisetron) Injection, extended release, for the prevention of
chemotherapy-induced nausea and vomiting (CINV) in patients receiving
highly emetogenic chemotherapy (HEC), will be presented at the American
Society of Clinical Oncology (ASCO) 2015 Breast Cancer Symposium on
Saturday, September 26, 2015 in San Francisco, CA.
Heron will present a poster and give an oral presentation for the
abstract titled "Phase III Study of APF530 versus Ondansetron with a
Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in